Oslo, Norway, 8 November 2016 – Targovax ASA (OSE: TRVX), a clinical stage company focused on developing and commercializing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, will announce its third quarter 2016 results on Thursday, 17 November 2016. A presentation by Targovax’s CEO, Øystein Soug, to investors, analysts and the press will take place in Oslo at 10:00 CET.
The results report and the presentation will be available at www.targovax.com in the Investors section from 07:00 CET.
The presentation will take place at 10:00 CET at:
The presentation will also be webcast live and can be accessed through www.targovax.com.
At 14:00 CET (08:00 EST) The company will host a telephone conference which will include a presentation of the results, following a Q&A session. CEO Øystein Soug will present the company. Call in details can be found below.
Norway Toll-Free Number: 800 19 747
Norway Toll Number: +472350 0559
UK Toll-Free Number: 08082370030
UK Toll Number: +442031394830
US Toll-Free Number: 1866 928 7517
US Toll Number: +1 718 873 9077
Access code: 23804707#
Please make sure to dial in at least 5-10 minutes ahead to complete your registration.
See attached list for more dial-in numbers.